Regulatory and Washington

Press enter to search
Close search
Open Menu

Regulatory and Washington

Regulatory news and trends in retail pharmacies.

Supplement industry calls on Congress to act on CBD

Four trade associations representing the dietary supplement industry have joined forces to urge Congress to provide legal clarity regarding the CBD marketplace.

Pharmacy groups urge Senate Finance Committee to close DIR fee loophole

Pharmacy organizations are urging the Senate Finance Committee to swiftly take action on DIR fee reform.

In a letter to the Trump administration, legislators noted that DIR fees on pharmacies participating in Part D grew by 45,000% between 2010 and 2017.

The Council for Responsible Nutrition recently praised two senators and two representatives for their work to introduce the SNAP Vitamin and Mineral Improvement Act

Among organizations and companies sharing their thoughts about cannabis and cannabis-derived products were the Food Marketing Institue, the National Cannabis Industry Association and manufacturer Functional Remedies.

Ahead of the Food and Drug Administration’s planned public hearing about cannabis, the Consumer Health Products Association is sharing its position on how it thinks the agency should view CBD.

The FDA has set a public hearing for May 31 on the safety of cannabis products.

Norman Sharpless, currently the head of the National Cancer Institute, will serve as acting FDA commissioner when Scott Gottlieb steps down next month.

Food and Drug Administration commissioner Scott Gottlieb will leave the agency next month after serving in this role for nearly two years.

PhRMA said that, among other efforts, it is working with the Association for Accessible Medicines to increase competition from generic drugs.

A record number of pharmacy advocates will keep the issue of DIR fee reform on the front burner at NACDS RxIMPACT day.

In comments to the House Ways and Means committee, the National Association of Chain Drug Stores pointed out that DIR fee reform can reduce patients’ out-of-pocket drug costs and overall healthcare spending,

The pilot will inform the development of the enhanced electronic, interoperable track-and-trace system for industry set to go into effect in 2023 as part of the Drug Supply Chain Security Act, the agency said.

The Trump Administration's plan is to lower drug costs by targeting backdoor rebates and encouraging direct discounts to patients.

Show More